{"_canonicalization":{"envelope_id":"axm_ + sha256(envelope minus {signature, axiom_id, anchors})","envelope_signature":"ed25519(envelope minus {signature, axiom_id})","json":"sort_keys=True, separators=(',',':'), ensure_ascii=False, allow_nan=False, utf-8","leaf_hash":"sha256(0x00 || canonical_json(envelope_full))","seal_signature":"ed25519(seal minus {signature, sig_algorithm})"},"axiom_id":"axm_a590383aed39f12e27ae3bbf9a2d93fceb368bd8f3a6cf5b6df4aaa1f973b018","bitcoin_anchor":{"bitcoin_attestations":[],"calendar_attestations":[],"ots_url":"","stamped_at":"","status":"pending_next_stamp"},"envelope":{"anchors":[{"chain":"crovia.axiom_graph","height":0,"merkle_proof":"spider_vendor_press_v1","root_at_anchor":"spider_vendor_press_v1"}],"axiom_id":"axm_a590383aed39f12e27ae3bbf9a2d93fceb368bd8f3a6cf5b6df4aaa1f973b018","axiom_type":"AX.OBS","body":{"axiom_subtype":"news.vendor_press.v1","category":"news","fingerprint":"64d874cc252e94e9693076fe3367fad83d1227752de8d7465116ec7c88c59431","published":"Fri, 15 May 2026 00:00:00 -0400","receipt_hash":"64d874cc252e94e9693076fe3367fad83d1227752de8d7465116ec7c88c59431","schema":"spider.news.vendor_press.v1","spider":"vendor_press","spider_record":{"axiom_subtype":"news.vendor_press.v1","category":"news","decision_hint":"POSITIVE","envelope_target":"AX.OBS","fingerprint":"64d874cc252e94e9693076fe3367fad83d1227752de8d7465116ec7c88c59431","observed_at":"2026-05-15T04:43:17.611638Z","parent_run_hash":"5c64f85625fabd323e9c4a1cf068c012fb88a248deda9a9ac702fb2f9799f2e5","published":"Fri, 15 May 2026 00:00:00 -0400","runtime_version":"0.1.0","schema":"spider.news.vendor_press.v1","source_status":200,"source_url":"https://export.arxiv.org/rss/cs.AI","spider":"vendor_press","summary_excerpt":"arXiv:2602.15019v5 Announce Type: replace \nAbstract: Bio-pharmaceutical innovation has shifted: many new drug assets now originate outside the United States and are disclosed primarily via regional, non-English channels. Recent data suggests over 85% of patent filings originate outside the U.S., with China accounting for nearly half of the global total; a growing share of scholarly output is also non-U.S. Industry estimates put China at 30% of global drug development, spanning 1,200+ novel candidates. In this high-stakes environment, failing to surface \"under-the-radar\" assets creates multi-billion-dollar risk for investors and business development teams, making asset scouting a coverage-critical competition where speed and completeness drive value. Yet today's Deep Research AI agents still lag human experts in achieving high-recall discovery across heterogeneous, multilingual sources without hallucinations. We propose a benchmarking methodology for drug asset scouting and a tuned, tre","title":"Hunt Globally: Wide Search AI Agents for Drug Asset Scouting in Investing, Business Development, and Competitive Intelligence","url":"https://arxiv.org/abs/2602.15019","vendor":"arxiv_cs_ai"},"summary":"arXiv:2602.15019v5 Announce Type: replace \nAbstract: Bio-pharmaceutical innovation has shifted: many new drug assets now originate outside the United States and are disclosed primarily via regional, non-English channels. Recent data suggests over 85% of patent filings originate outside the U.S., with China accounting for nearly half of the global total; a growing share of scholarly output is also non-U.S. Industry estimates put China at 30% of global drug development, spanning 1,200+ novel candidates. In this high-stakes environment, failing to surface \"under-the-radar\" assets creates multi-billion-dollar risk for investors and business development teams, making asset scouting a coverage-critical competition where speed and completeness drive value. Yet today's Deep Research AI agents still lag human experts in achieving high-recall discovery across heterogeneous, multilingual sources without hallucinations. We propose a benchmarking methodology for drug asset scouting and a tuned, tre","title":"Hunt Globally: Wide Search AI Agents for Drug Asset Scouting in Investing, Business Development, and Competitive Intelligence","vendor":"arxiv_cs_ai"},"confidence":{"method":"deterministic"},"decision":"POSITIVE","issued_at":"2026-05-15T04:43:17Z","notes":"Spider vendor_press (news) news.vendor_press.v1","object":{"captured_by":"crovia.spider.vendor_press","primary_source_url":"https://arxiv.org/abs/2602.15019"},"predecessors":[],"schema":"crovia.axiom.v1","signature":"ed25519:28fc23590d64fa507841352be9c4aa48841e8887079feb78e4291459450aea7a8ff88c05cf257ce31f59536dbceedb6208cc743a8f1348b630923acc5f07f80e","signer":"crovia.substrate","subject":{"observed_at":"2026-05-15T04:43:17Z","source_collector":"spider:vendor_press","target_id":"https://arxiv.org/abs/2602.15019"},"tsa":{"authority":"crovia.substrate.bootstrap","rfc3161_token":"{\"kind\":\"crovia.bootstrap.tsa\",\"source_jsonl\":\"/opt/crovia/spider/data/news/vendor_press_v1.jsonl\",\"source_seal_merkle_root\":\"spider_vendor_press_v1\",\"upgrade_path\":\"Sessione H \\u2014 OpenTimestamps weekly anchor\"}"},"zk_mode":"clear","zk_proof":null},"ledger":{"leaf_hash":"35a9230b532c87d663337ad39e65f6a36f8aea99239c421b4f82bf09d4723fc5","leaf_index":134697,"ledger_path":"/opt/crovia/substrate/axiom_ledger.jsonl"},"merkle_proof":{"hash_alg":"sha256","leaf_prefix":"0x00","node_prefix":"0x01","odd_leaf_rule":"duplicate_last","path":[{"sibling":"50a9638200e648d5159fa0ed8ff558896b8ddcf3010d1b3f1b4d694709a20964","side":"left"},{"sibling":"e1ffe72136b982348a12dd5e5b74103f59538e51144a9dabf012bb6784d8ac3d","side":"right"},{"sibling":"7befe93198c877d17a767d0df35d93958edcdb3afdc97e6ee00808702c13c0c1","side":"right"},{"sibling":"e81fd0a70be54cb824cfabaa3ba7393ee242c2edd2676c311e0b228798f40dfe","side":"left"},{"sibling":"0a44cbd29dd0fd17c33b1ad0353f68daeab833a36c05bbbb08ddb0eeb69f7e33","side":"right"},{"sibling":"07b2eef99e6d312bb62f3cf6bba178f98b9640fc1d4891ac30c180185eeca473","side":"left"},{"sibling":"bca4711cdb0765a339b3db05a85ed17fb8e65a24e2b58309e8137da50874715e","side":"right"},{"sibling":"d8ac22bfe982d5dc7f00879b0b1dfae8f4e95a38a6242933cbebb3b7271d5704","side":"right"},{"sibling":"a17a0eaa87574a308e2c02cf125072b9e69566b9e8d6d2e64a02880192b885d5","side":"right"},{"sibling":"6bd0475fd3a73322a4f73095c96b072de89e462ce5839161aa552e0208619bce","side":"left"},{"sibling":"36672459e5ed50c64ee1842b69cb6d2eb682c2a04844555be8d124257571994a","side":"left"},{"sibling":"727783827652adfa99c455bd80a01bfb33836228e51068b4f654ef3da468ca69","side":"left"},{"sibling":"623194cd30880ed223e306737fdb111aa0d781751bfc47553c404a6af6aad2c4","side":"right"},{"sibling":"fc8f53ed42756907fb79ee19a4ed09f72c560e5302b3d98198b96bf1da635a4a","side":"right"},{"sibling":"d6607539da7ba39ec68be2d12f27ed6768766c745e3120fd915f88c5e288e07c","side":"right"},{"sibling":"b63408a424d27cd6a75e0fb155e69a58a328f41e9cb9dba1eddef9a5289cc7fd","side":"right"},{"sibling":"356fb36a4e188f03d7a05c54cd8789bdd40eda454b9bc9560f667acc08e6c4e0","side":"right"},{"sibling":"d841ad93efda0869e5eb97678f348f03f5caab4353e05ff4bf18f47fb945b822","side":"left"}]},"schema":"crovia.axiom_proof.v1","seal":{"first_collector_run_id":"","first_receipt_hash":"","jsonl_path":"/opt/crovia/substrate/axiom_ledger.jsonl","key_id":"430895f101d38164","last_collector_run_id":"","last_receipt_hash":"","leaf_count":134886,"merkle_root":"c6c7ae28c065bced89e7f844216b073f1a7cc4b378db0d41a98bcd21b28066db","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","run_id":"hourly_json_retrofit_20260515T053701Z","schema":"crovia.seal.v1","seal_family_version":"crovia-seal-family/1","seal_kind":"substrate_batch","sealed_at":"2026-05-15T05:37:26Z","sig_algorithm":"ed25519","signature":"5a3978c26017daf4104adbb3e1c3099c5750157acbfc7242ece1815dc6740fe08a690291ce0afe42011e20cc565b5ebe64ec016bf658b5bab563a63337985c05","signer_version":"1.1.0"},"trust_root":{"key_id":"430895f101d38164","public_key_hex":"cf742e26f75669dc673cb5c0786a1ae23ae8ca19c347317192ce40c28a7ff25c","signature_algorithm":"ed25519","url":"/registry/canon/TRUST_ROOT.md"},"verifier":{"spec":"/registry/canon/AXIOM_RECEIPT_v1.md","url":"/v/axm_a590383aed39f12e27ae3bbf9a2d93fceb368bd8f3a6cf5b6df4aaa1f973b018"}}